Ruth Coleman

Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial
Moritz J. Hundertmark, Amanda Adler, Charalambos Antoniades, Ruth Coleman, Julian L. Griffin, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Daniel Massey, Jack J.J.J. Miller, Joanne E. Milton, Shveta Monga, Ferenc E. Mózes, Areesha Nazeer, Betty Raman, Oliver Rider, Christopher T. Rodgers, Ladislav Valkovic, Eleanor Wicks, Masliza Mahmod, Stefan Neubauer
Circulation 2023. Epub:18-Apr-2023. PMID:37070436. doi:10.1161/CIRCULATIONAHA.122.062021

Joint longitudinal and time-to-event modeling compared with standard Cox modeling in patients with type 2 diabetes with and without established cardiovascular disease: an analysis of the EXSCEL trial
Abderrahim Oulhaj, Faisal Aziz, Abubaker Suliman, Nayyar Iqbal, Ruth L Coleman, Rury R Holman, Harald Sourij
Diabetes Obes Metab. 2023;25:1261-1270. Published:May-2023. Epub:12-Jan-2023. PMID:36635232. doi:10.1111/dom.14975

11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial
Nantia Othonos, Riccardo Pofi, Anastasia Arvaniti, Sarah White, Ilaria Bonaventura, Nikolaos Nikolaou, Ahmad Moolla, Thomas Marjot, Roland H Stimson, André P van Beek, Martijn van Faassen, Andrea M Isidori, Elizabeth Bateman, Ross Sadler, Fredrik Karpe, Paul M Stewart, Craig Webster, Joanne Duffy, Richard Eastell, Fatma Gossiel, Thomas Cornfield, Leanne Hodson, K Jane Escott, Andrew Whittaker, Ufuk Kirik, Ruth L Coleman, Charles A B Scott, Joanne E Milton, Olorunsola Agbaje, Rury R Holman, Jeremy W Tomlinson
Nat Commun. 2023;14:1025. Published:23-Feb-2023. Epub:23-Feb-2023. PMID:36823106. doi:10.1038/s41467-023-36541-w

Risk prediction models for incident type 2 diabetes in Chinese people with intermediate hyperglycemia: a systematic literature review and external validation study
Shishi Xu, Ruth L. Coleman, Qin Wan, Yeqing Gu, Ge Meng, Kun Song, Zumin Shi, Qian Xie, Jaakko Tuomilehto, Rury R. Holman, Kaijun Niu and Nanwei Tong
Cardiovasc Diabetol. 2022;21:182. Published:13-Sep-2022. PMID:36100925. doi:10.1186/s12933-022-01622-5

The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized controlled trials
David Preiss, Enti Spata, Rury R. Holman, Ruth L. Coleman, Laura Lovato, Henry Ginsberg, Jane Armitage
Diabetes Care 2022;45:e1-e2. Published:Jan-2022. Epub:07-Dec-2021. PMID:34876531. doi:10.2337/dc21-1439

Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88
Marcus Lind, Henrik Imberg, Ruth L. Coleman, Olle Nerman, and Rury R. Holman
Diabetes Care 2021;44:2231-2237. Published:Oct-2021. Epub:08-Jul-2021. PMID:34244332. doi:10.2337/dc20-2439

Predicting the Risk of Developing Type 2 diabetes in Chinese People who have Coronary Heart Disease and Impaired Glucose Tolerance
Shishi Xu, Charles A. B. Scott, Ruth L. Coleman, Jaakko Tuomilehto, Rury R. Holman
Journal of Diabetes 2021;13:817-826. Published:Oct-2021. Epub:04-Mar-2021. PMID:33665904. doi:10.1111/1753-0407.13175

Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
Moritz J. Hundertmark, Olorunsola F. Agbaje, Ruth Coleman, Jyothis T. George, Rolf Grempler, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Joanne E. Milton, Heiko G. Niessen, Oliver Rider, Christopher T. Rodgers, Ladislav Valkovic, Eleanor Wicks, Masliza Mahmod and Stefan Neubauer
ESC Heart Failure 2021;8:2580-2590. Published:Aug-2021. Epub:06-May-2021. PMID:33960149. doi:10.1002/ehf2.13406

Increased Risk of Incident Heart Failure and Death is Associated with Insulin Resistance in People with Newly- Diagnosed Type 2 Diabetes: UKPDS 89
Malgorzata Wamil, Ruth L. Coleman, Amanda I. Adler, John McMurray, Rury R. Holman
Diabetes Care 2021;44:1-8. Published:Aug-2021. doi:10.2337/dc21-0429

Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension: A Systematic Review and Individual Participant-based Meta-analysis
Stephen P Juraschek, Jiun-Ruey Hu, Jennifer L Cluett, Anthony Ishak, Carol Mita, Lewis A. Lipsitz, Nigel Beckett, Ruth L. Coleman, William Cushman, Greg Grandits, Rury R. Holman, Edgar R Miller 3rd, James Neaton, Ruth Peters, Jan A. Staessen, Lutgarde Thijs, Kenneth J Mukamal
Ann Int Med. 2020;174:58-68. Published:Jan-2021. Epub:10-Sep-2020. PMID:32909814. doi:10.7326/M20-4298

Predicting Heart Failure Events in Patients with Coronary Heart Disease and Impaired Glucose Tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial
Malgorzata Wamil, John JV McMurray, Charlie AB Scott, Ruth L Coleman, Yihong Sun, Eberhard Standl, Lars Rydèn, Rury R Holman
Diabetes Res Clin Pract. 2020;170:108488. Published:Dec-2020. Epub:06-Oct-2020. PMID:33035598. doi:10.1016/j.diabres.2020.108488

Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials
Jin J. Zhou, Ruth Coleman, Rury R. Holman, Peter Reaven
Diabetologia 2020;63:2482-2485. Published:Nov-2020. Epub:21-Sep-2020. PMID:32954444. doi:10.1007/s00125-020-05273-7

Risk of anemia with metformin use in type 2 diabetes: A MASTERMIND study
Louise A Donnelly, John M Dennis, Ruth L Coleman, Naveed Sattar, Andrew T Hattersley, Rury R Holman, Ewan R Pearsonson
Diabetes Care 2020;43:2493-2499. Published:Oct-2020. Epub:14-Aug-2020. PMID:32801130. doi:10.2337/dc20-1104

Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial
Hertzel C. Gerstein, Ruth L. Coleman, Charles A.B. Scott, Shishi Xu, Jaakko Tuomilehto, Lars Rydén, Rury R. Holman for the ACE Study Group
Diabetes Care 2020;43:2242-2247. Published:Sep-2020. Epub:08-Jul-2020. PMID:32641379. doi:10.2337/dc19-2046

Predicting Post One-year Durability of Glucose-lowering Monotherapies in Patients with Newly-diagnosed Type 2 Diabetes Mellitus - A MASTERMIND Precision Medicine Approach (UKPDS 87)
Olorunsola F. Agbaje, Ruth L. Coleman, Andrew T. Hattersley, Angus G. Jones, Ewan R. Pearson, Beverley M. Shields, and Rury R. Holman, for the MASTERMIND consortium
Diabetes Res Clin Pract. 2020;166:108333. Published:Aug-2020. Epub:20-Jul-2020. PMID:32702468. doi:10.1016/j.diabres.2020.108333

Can the Cardiovascular Risk Reductions Observed with Empagliflozin in the EMPA-REG OUTCOME Trial be Explained by the Changes Seen in Conventional Cardiovascular Risk Factor Levels?
Ruth L. Coleman, Alastair M. Gray, Uli C. Broedl, David Fitchett, Jyothis T George, Hans-Juergen Woerle, Bernard Zinman, and Rury R. Holman
Diabetes Obes Metab. 2020;22:1151-1156. Published:Jul-2020. Epub:01-Mar-2020. PMID:32115840. doi:10.1111/dom.14017

Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)
Ernesto Maddaloni, Ruth L. Coleman, Olorunsola F. Agbaje, Raffaella Buzzetti, Rury R. Holman
Lancet Diabetes Endocrinol 2020;8:206-15. Published:Mar-2020. Epub:04-Feb-2020. PMID:32032540. doi:10.1016/S2213-8587(20)30003-6

Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes
Ruth L. Coleman, Charles A. B. Scott, Zhihui Lang, M. Angelyn Bethel, Jaakko Tuomilehto and Rury R. Holman
Cardiovasc Diabetol 2019;18:135. Published:17-Oct-2019. PMID:31623625. doi:10.1186/s12933-019-0933-y

Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates
Mostafa SA, Coleman RL, Agbaje OF, Gray A, Holman RR, Bethel MA
J Diabetes Complications 2019;33:69-74. Published:Jan-2019. Epub:10-Oct-2018. PMID:30361000. doi:10.1016/j.jdiacomp.2018.09.017

Long-term Risk of Cardiovascular Disease in Individuals with Latent Autoimmune Diabetes of Adults (UKPDS 85)
E. Maddaloni, R.L.Coleman, P.Pozzilli, R.R. Holman
Diabetes Obese Metab. 2019;2019:2115-2122. Epub:17-May-2019. PMID:31099472. doi:10.1111/dom.13788

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
S. A. Mostafa, R. L. Coleman, O. F. Agbaje, A. M. Gray, R. R. Holman and M. A. Bethel
Diabet Med. 2018;35:72-77. Published:Jan-2018. Epub:23-Oct-2017. PMID:29057545. doi:10.1111/dme.13533

Baseline Characteristics and Temporal Differences in Acarbose Cardiovascular Evaluation (ACE) Trial Participants
Michael J. Theodorakis, Ruth L. Coleman, Huimei Feng, Juliana Chan, Jean-Louis Chiasson, Junbo Ge, Hertzel C. Gerstein, Yong Huo, Zhihui Lang, John J. McMurray, Lars Rydén, Stefan Schröder, Michal Tendera, Jaakko Tuomilehto, Wenying Yang, Dayi Hu, Changyu Pan and Rury R. Holman for the ACE Study Group
Am Heart J 2017;199:170-175. Published:May-2018. Epub:10-Sep-2017. PMID:29754657. doi:10.1016/j.ahj.2017.09.001

Health selection into neighborhoods among patients enrolled in a clinical trial
Mariana Arcaya, Ruth L. Coleman, Fahad Razak, Maria L. Alva, Rury R. Holman
Preventive Medicine Reports 2017;8:51–54. Published:Dec-2017. Epub:28-Jul-2017. PMID:28924547. doi:10.1016/j.pmedr.2017.07.003

Effects of Acarbose on Cardiovascular and Diabetes Outcomes in Patients with Coronary Heart Disease and Impaired Glucose Tolerance: A Randomised Controlled Trial
Rury R Holman, Ruth L Coleman, Juliana C N Chan, Jean-Louis Chiasson, Huimei Feng, Junbo Ge, Hertzel C Gerstein, Richard Gray, Yong Huo, Zhihui Lang, John J McMurray, Lars Rydén, Stefan Schröder, Yihong Sun, Michael J Theodorakis, Michal Tendera, Lynne Tucker, Jaakko Tuomilehto, Yidong Wei, Wenying Yang, Duolao Wang, Dayi Hu, Changyu Pan for the ACE Study Group
Lancet Diabetes Endocrinol. 2017;5:877-86. Published:Nov-2017. Epub:13-Sep-2017. PMID:28917545. doi:10.1016/S2213-8587(17)30309-1
[Slides] [Slides #2]
Erratum in :
Lancet Diabetes Endocrinol. 2019;5:PE5, Print:May-2019, Epub:01-May-2019, doi:10.1016/S2213-8587(19)30063-4

Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis
Rakesh Malhotra, Hoang Anh Nguyen, Oscar Benavente, Mihriye Mete, Barbara Howard, Jonathan Mant, Michelle C. Odden, Carmen A. Peralta, Alfred Cheung, Girish Nadkarni, Ruth L. Coleman, Rury R. Holman, Alberto Zanchetti, Ruth Peters, Nigel Beckett, Jan Staessen, Joachim H. Ix
JAMA Intern Med 2017;177:1498-1505. Published:Oct-2017. Epub:05-Sep-2017. PMID:28873137. doi:10.1001/jamainternmed.2017.4377

Microvascular outcomes in type 2 diabetes - Authors' reply
Sophia Zoungas, Hertzel C Gerstein, Rury R Holman, Peter Reaven, Mark Woodward, Hisatomi Arima, Ruth L Coleman, John Chalmers, the Collaborators on Trials of Lowering Glucose (CONTROL) writing group
Lancet Diabetes Endocrinol 2017;5:580. Published:Aug-2017. PMID:28732664. doi:10.1016/S2213-8587(17)30185-7

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group
Lancet Diabetes Endocrinol. 2017;5:431-437. Published:Jun-2017. Epub:29-Mar-2017. PMID:28365411. doi:10.1016/S2213-8587(17)30104-3

Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin
Kaixin Zhou, Sook Wah Yee, Eric L Seiser, Nienke van Leeuwen, Roger Tavendale, Amanda J Bennett, Christopher J Groves, Ruth L Coleman, Amber A van der Heijden, Joline W Beulens, Catherine E de Keyser, Linda Zaharenko, Daniel M Rotroff, Mattijs Out, Kathleen A Jablonski, Ling Chen, Martin Javorský, Jozef Židzik, Albert M Levin, L Keoki Williams, Tanja Dujic, Sabina Semiz, Michiaki Kubo, Huan-Chieh Chien, Shiro Maeda, John S Witte, Longyang Wu, Ivan Tká?, Adriaan Kooy, Ron H N van Schaik, Coen D A Stehouwer, Lisa Logie, MetGen Investigators, DPP Investigators, ACCORD Investigators, Calum Sutherland, Janis Klovins, Valdis Pirags, Albert Hofman, Bruno H Stricker, Alison A Motsinger-Reif, Michael J Wagner, Federico Innocenti, Leen M ’t Hart, Rury R Holman, Mark I McCarthy, Monique M Hedderson, Colin N A Palmer, Jose C Florez, Kathleen M Giacomini & Ewan R Pearson
Nature Genetics 2016;48:1055-9. Published:Sep-2016. Epub:08-Aug-2016. PMID:27500523. doi:10.1038/ng.3632

Evaluation of a Self-Administered Oral Glucose Tolerance Test
M. Angelyn Bethel, Hermione C. Price, Harald Sourij, Sarah White, Ruth L. Coleman, Arne Ring, Irene E. C. Kennedy, Lynne Tucker, and Rury R. Holman
Diabetes Care 2013;36:1483-1488. Published:Jun-2013. Epub:15-Jan-2013. PMID:23321216. doi:10.2337/dc12-0643

Prognostic Significance of Silent Myocardial Infarction in Newly-Diagnosed Type 2 Diabetes: UKPDS 79
Timothy M.E. Davis; Ruth L. Coleman; Rury R. Holman
Circulation 2013;127:980-987. Published:05-Mar-2013. Epub:29-Jan-2013. PMID:23362315. doi:10.1161/CIRCULATIONAHA.112.000908

Predicting 6-year mortality risk in patients with type 2 diabetes: response to Wells et al.
Paul S, Coleman RL, Price HC, Farmer AJ
Diabetes Care 2009;32:e60. Published:May-2009. PMID:19407070. doi:10.2337/dc09-0183
[Abstract]

Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
Simmons RK, Coleman RL, Price HC, Holman RR, Khaw K, Wareham NJ, Griffin SJ
Diabetes Care 2009;32:708-713. Published:Apr-2009. Epub:29-Dec-2008. PMID:19114615. doi:10.2337/dc08-1918
[Abstract]

Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes
Price HC, Coleman RL, Stevens RJ, Holman RR
Diabetologia 2009;52:394-397. Published:Mar-2009. Epub:02-Dec-2008. PMID:19048226. doi:10.1007/s00125-008-1231-5
[Abstract]

Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes
Ruth L. Coleman, Richard J. Stevens, Ravi Retnakaran, and Rury R. Holman
Diabetes Care 2007;30:1292-1293. Published:May-2007. Epub:08-Feb-2007. PMID:17290036. doi:10.2337/dc06-1358

Non-HDL Cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes
Holman RR, Coleman RL, Shine BS, Stevens RJ
Diabetes Care 2005;28:1796-1797. Published:Jul-2005. PMID:15983339. doi:10.2337/diacare.28.7.1796

Framingham risk equations underestimate coronary heart disease risk in diabetes
R. J. Stevens, R. L. Coleman, R. R. Holman
Diab Med. 2005;22:228. Published:Feb-2005. Epub:19-Jan-2005. PMID:15660747. doi:10.1111/j.1464-5491.2005.01387.x

Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66
Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR
Diabetes Care 2004;27:201-207. Published:Jan-2004. PMID:14693990. doi:10.2337/diacare.27.1.201
[Abstract]